Odds

Record Store Day Blondie News

Retrieved on: 
Thursday, February 17, 2022
Longitudinal wave, Paramount Theater, Time, FACE, Sunday Girl, Pollinator, Parallel Lines, NME, Billboard (magazine), Photography, Paramount, Blondie, Channel 4's Comedy Gala (2011 TV program), Tribeca Film Festival, Heart of Glass, The Rolling Stones, Sheffield, Odds, Billboard, Rolling Stone's 500 Greatest Albums of All Time, Sands of Time (Jay and the Americans album), All Time Low, Sheffield Doc/Fest, The Ronettes, Channel, Pitchfork, Blender, Nightclub, Toy, Film

LOS ANGELES, Feb. 17, 2022 /PRNewswire/ -- Exclusively for Record Store Day (April 23, 2022), Blondie, one of the most influential bands to emerge from New York's punk scene, will release a limited edition EP featuring one of their most famous, endearing, and successful singles "Sunday Girl."

Key Points: 
  • LOS ANGELES, Feb. 17, 2022 /PRNewswire/ -- Exclusively for Record Store Day (April 23, 2022), Blondie, one of the most influential bands to emerge from New York's punk scene, will release a limited edition EP featuring one of their most famous, endearing, and successful singles "Sunday Girl."
  • "Exactly why the song became Sunday Girl, I am not sure, other than Chris and I had a silly kitty named Sunday Man.
  • The bespoke Record Store Day release will include a deluxe two-disc, four-track 7" set on red and yellow vinyl, set inside a stunning gatefold sleeve featuring rare photos from the period.
  • Tracklisting for the Sunday Girl Record Store Day Release:

BlueSpace.ai Debuts 4D Predictive Perception Software at CES - Enabling Autonomy at Scale

Retrieved on: 
Tuesday, January 18, 2022
Aurora, Nexus, Research, Technology, Supercruise, Stanford University, FMCW, Mobileye, Motion, AV, Genomics, Perception, Radar, McKinsey & Company, Safety, Cruise (autonomous vehicle), Bluespace (software), CEO, Waymo, GLOBE, General Motors, Leadership, Color, Lidar, Industry, Silicon, Odds, Robotaxi, Velodyne Lidar, Data collection, CPU, CES, Google, 3D printing, Apple

EMERYVILLE, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- BlueSpace.ai showcased its breakthrough 4D Predictive Perception technology at CES 2022.

Key Points: 
  • EMERYVILLE, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- BlueSpace.ai showcased its breakthrough 4D Predictive Perception technology at CES 2022.
  • This perception software works with next generation 4D sensors - imaging radar or frequency modulated continuous wave (FMCW) LiDAR .
  • Given the price competitiveness and improving performance, CES 2022 highlighted the significant interest in imaging radar from across the AV industry.
  • Perception and prediction will need to be robust enough to handle endless edge cases in diverse ODDs to enable trucking, robotaxi, logistics autonomy
    BlueSpace's 4D Predictive Perception software addresses both effectively.If you weren't able to make it to CES, here's the link to their 4D Predictive Perception software .

Poll Shows Newark Voter Support for Charter Schools Remains Strong During Pandemic, but Shows Large Decline in Those Who Think Education is on Right Track

Retrieved on: 
Friday, January 14, 2022
Research, Profile, Change Research, Beat the Odds, Population, Boston University, Student, GLOBE, Public opinion, Leadership, School, Reading, Parent, Dream, Education, New Jersey Department of Education, Municipality, Odds, Online gambling, Tutoring, Residential care

60 percent of Newark voters have a favorable opinion of the city's charter schools.

Key Points: 
  • 60 percent of Newark voters have a favorable opinion of the city's charter schools.
  • Also by a two-to-one margin, voters believe charter schools help - not harm - public education in the city.
  • Support for public charter schools extends across political divisions - more than 60 percent of both Democrats and Republicans support the city's charter schools.
  • The poll comes after years of growing enrollment at the city's charter schools that occurred as part of a citywide improvement strategy.

Bold Therapeutics Extends South Korea Option Agreement for BOLD-100, a First-in-Class Anti-Resistance Therapeutic

Retrieved on: 
Thursday, January 13, 2022
GRP78, Stomach, National Cancer Center, Samsung Medical Center, Reactive oxygen species, Unfolded protein response, Cancer, Douglas BTD Destroyer, CEO, ROS, UPR, DNA, Therapy, Odds, Seoul National University Hospital, DNA repair, Induced cell cycle arrest, Emphasis (typography), FOLFOX, Cell death, FDA, Pharmaceutical industry

VANCOUVER, British Columbia, Jan. 13, 2022 /PRNewswire/ --Bold Therapeutics, a clinical-stage biopharmaceutical company developing BOLD-100, is pleased to announce an extension of the option agreement with an undisclosed publicly traded South Korean biopharmaceutical company, originally executed in May 2020, for development and commercialization rights to BOLD-100 in South Korea.

Key Points: 
  • VANCOUVER, British Columbia, Jan. 13, 2022 /PRNewswire/ --Bold Therapeutics, a clinical-stage biopharmaceutical company developing BOLD-100, is pleased to announce an extension of the option agreement with an undisclosed publicly traded South Korean biopharmaceutical company, originally executed in May 2020, for development and commercialization rights to BOLD-100 in South Korea.
  • Bold Therapeutics' BOLD-100 is a first-in-class ruthenium-based small molecule therapeutic that (1) alters the unfolded protein response (UPR) through selective GRP78 inhibition; and (2) induces reactive oxygen species (ROS) which causes DNA damage and cell cycle arrest.
  • "As our partner is one of the fastest growing and most respected pharmaceutical companies in South Korea, we are honored to extend this option agreement that allows us to further leverage their substantial expertise in oncology development," said E. Russell McAllister, CEO of Bold Therapeutics.
  • For more information about Bold Therapeutics, please visit the company's website at www.bold-therapeutics.com

Cellectar Presented Data from its Ongoing Phase 2 CLOVER-1 Study of Iopofosine I-131 at the 63rd ASH Annual Meeting and Exposition

Retrieved on: 
Monday, December 13, 2021
Lymphoma, Rhabdomyosarcoma, Exchange, European Commission, Christian democracy, NASDAQ, Anemia, Dexamethasone, Risk, Patient, LinkedIn, FDA, PFS, Cancer, Neuroblastoma, Regulation, Osteosarcoma, ORR, Odds, Mayo Clinic Florida, Arrhythmia, U.S. Securities and Exchange Commission, B-cell lymphoma, Thrombocytopenia, MM, CBR, Safety, Security (finance), GLOBE, Bleeding, ASH, Macroglobulinemia, Sarcoma, Mayo Clinic, News, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Peripheral neuropathy, WM, COVID-19, PDC, Neutropenia, CEO, Research, Marketing, Exposition, Multiple myeloma, DLBCL, Twitter, Degenerative disease, Bone marrow suppression, Food, Poster, Drug discovery, Cytopenia, Brain, DCR, Division, Pharmaceutical industry, Medicine, Facebook, Lead

FLORHAM PARK, N.J., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, presented data from 11 multiple myeloma patients from the company’s ongoing Phase 2 CLOVER-1 study of iopofosine I-131 in a poster at the American Society of Hematology (ASH) Annual Meeting and Exposition.

Key Points: 
  • Treatment emergent adverse events were mostly limited to bone marrow suppression in line with prior observations.
  • We believe iopofosine I-131s demonstrated ability to specifically target cancer cells potentially represents an important advancement in cancer-targeting treatments.
  • We look forward to sharing additional data as the Phase 2 CLOVER-1 study matures.
  • The WM cohort will enroll up to 50 patients to evaluate the efficacy and safety of iopofosine for marketing approval.

Robotic Research Announces $228 Million Series A Funding Round to Scale Autonomous Technology Commercially

Retrieved on: 
Thursday, December 9, 2021
Software, Hardware, Electronic Design Automation, Public Transport, General Automotive, Technology, Automotive, Trucking, Automotive Manufacturing, Transport, Manufacturing, Logistics, Supply Chain Management, Company, UBS, LLP, Cravath, Swaine & Moore, Odds, Research, Weather, CEO, Covington & Burling, Robot research initiative, Transport, SoftBank Group, OEM, Partner (business rank), Multimedia, Senior, Robotics, Solution, Food delivery, Heavy equipment

Robotic Research, a global leader in autonomous mobility and robotics solutions, today announced a $228 million funding roundthe first outside capital the company has raised.

Key Points: 
  • Robotic Research, a global leader in autonomous mobility and robotics solutions, today announced a $228 million funding roundthe first outside capital the company has raised.
  • Investors in the Series A round include SoftBank Vision Fund 2, Enlightenment Capital, Crescent Cove Advisors, Henry Crown and Company, and Luminar Technologies, Inc.
  • Robotic Research has successfully deployed autonomous and robotics solutions on roadways around the globe as well as in the industrys harshest, unstructured environments.
  • Robotic Research is working alongside Luminar on strategic opportunities to advance autonomy and has selected Luminar as its long-range lidar provider.

Cellectar Biosciences Announces Poster Presentation at the 63rd American Society for Hematology Annual Meeting and Exposition

Retrieved on: 
Wednesday, December 8, 2021
Rhabdomyosarcoma, Twitter, Risk, Regulation, U.S. Securities and Exchange Commission, Research, Patient, B-cell lymphoma, GLOBE, European Commission, Sarcoma, Christian democracy, Multiple myeloma, Osteosarcoma, Security (finance), 131, Safety, Lymphoma, Odds, Cancer, Food, PDC, News, Exchange, WM, Drug discovery, DLBCL, COVID-19, Brain, Neuroblastoma, FDA, Poster, NASDAQ, LinkedIn, Marketing, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CLR, Society, MM, ASH, Pharmaceutical industry

Iopofosine is a small-molecule Phospholipid Drug Conjugate designed to provide targeted delivery of iodine-131 (radioisotope) directly to cancer cells, while limiting exposure to healthy cells.

Key Points: 
  • Iopofosine is a small-molecule Phospholipid Drug Conjugate designed to provide targeted delivery of iodine-131 (radioisotope) directly to cancer cells, while limiting exposure to healthy cells.
  • Iopofosine was also granted Rare Pediatric Disease Designation (RPDD) for the treatment of neuroblastoma, rhabdomyosarcoma, Ewings sarcoma and osteosarcoma.
  • Cellectar Biosciences is focused on the discovery and development of drugs for the treatment of cancer.
  • These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.

CytoDyn’s CRO in Brazil Met with ANVISA to Modify CD16 Trial for Critically Ill COVID-19 Patients to Expedite Interim Analysis After 51 Patients, Potentially in 1Q2022

Retrieved on: 
Wednesday, December 8, 2021
Research, Infectious Diseases, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, U.S. Securities and Exchange Commission, Mean time to recovery, NASH, Forward-looking statement, Company, CRO, IV, Social conditioning, Brazilian Health Regulatory Agency, SARS, Security (finance), OTCQB, ANVISA, ECMO, Food, Injection, Patient, Vaccine, Partnership, BLA, Triple-negative breast cancer, Form 10-K, Odds ratio, HIV, Optimism, CD16, CMC, Odds, Survival rate, Standard of care, Time, COVID-19, DSMB, XV, Viral load, Clinical trial, FDA, Survival, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Risk, CCR5, 100,000, Compliance, ARO, Calendar, Pharmaceutical industry

By comparison, in the previous CD12 trial (a phase 3 trial for COVID-19 severe-to-critical ill patients) in the USA, patients received only two weekly doses of 700 mg of leronlimab via sub-cutaneous injections.

Key Points: 
  • By comparison, in the previous CD12 trial (a phase 3 trial for COVID-19 severe-to-critical ill patients) in the USA, patients received only two weekly doses of 700 mg of leronlimab via sub-cutaneous injections.
  • The primary endpoint in this study was based on the valuable information we had generated from the past CD12 trial.
  • The p-value for length of hospital stay for the critically ill patients who were on invasive mechanical ventilator or ECMO was 0.005.
  • The primary endpoint of the CD16 trial in Brazil is Time to Recovery, which is similar to this endpoint.

Sports Betting Radio Personality Matt Perrault, Longtime Bookmaker Dave Sharapan Join American Affiliate, Launch New Show

Retrieved on: 
Thursday, November 18, 2021
News, Sport, Industry, Gambling, The Book, Education, Pittsburgh Steelers, Book, Radio, View, Odds, Super Bowl X, Affiliation, Multimedia, Casino, Online gambling

LAS VEGAS, Nov. 18, 2021 /PRNewswire/ --Today, leading gambling media company American Affiliate announced the addition of sports betting radio host Matt Perrault and longtime bookmaker Dave Sharapan to its growing team of sports gambling media personalities.

Key Points: 
  • LAS VEGAS, Nov. 18, 2021 /PRNewswire/ --Today, leading gambling media company American Affiliate announced the addition of sports betting radio host Matt Perrault and longtime bookmaker Dave Sharapan to its growing team of sports gambling media personalities.
  • The Book, a new sports betting livestream and podcast on Props.com , an American Affiliate site.
  • The Book while spending four years doing radio segments together on Perrault's nationally syndicated sports gambling show.
  • American Affiliate (AmAff) is a next-gen gambling affiliate and media company focused on the legal U.S. sports betting and online gambling market.

Cellectar’s Iopofosine I-131 Exhibits Signals of Efficacy in Phase I Study for Pediatric Brain and Solid Tumors

Retrieved on: 
Tuesday, November 16, 2021
Osteosarcoma, Safety, HGG, Diffuse intrinsic pontine glioma, Cancer, Pediatric ependymoma, News, Sarcoma, Neoplasm, European Commission, Exchange, Security (finance), NASDAQ, B-cell lymphoma, DMC, Outline, Food, Ewing's sarcoma, Glioblastoma, Odds, Brain, COVID-19, MM, Research, DLBCL, Regulation, Astrocytoma, Twitter, Multiple myeloma, Neuroblastoma, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, GLOBE, WM, LinkedIn, Collection, Rhabdomyosarcoma, Drug discovery, Christian democracy, Survival, PDC, Central nervous system, Marketing, PFS, Patient, Risk, FDA, Lymphoma, Pharmaceutical industry, Medical imaging

Initial responses to iopofosine I-131 in relapsed pediatric brain tumors are most encouraging.

Key Points: 
  • Initial responses to iopofosine I-131 in relapsed pediatric brain tumors are most encouraging.
  • Pediatric HGGs are a collection of aggressive brain and central nervous system tumor subtypes including diffuse intrinsic pontine gliomas, glioblastomas, astrocytomas and ependymomas.
  • Iopofosine is currently being evaluated in the CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstroms macroglobulinemia (WM), a Phase 2b study in r/r multiple myeloma (MM) patients and the CLOVER-2 Phase 1 study for a variety of pediatric cancers.
  • The company is also evaluating iopofosine in highly refractory multiple myeloma patients in its Phase 2 CLOVER-1 study and relapsed/refractory pediatric cancer patients with sarcomas or brain tumors in the Phase 1 CLOVER-2 study.